Hosted on MSN24d
Boral Capital sets $22 target on Scilex shares, rating BuyThe standout in Scilex's pipeline, according to Boral Capital, is SEMDEXA, a clinical-stage dexamethasone gel that has shown positive results in Phase 3 trials for sciatica. The analyst firm views ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback